Pressemitteilung BoxID: 69574 (4SC AG)
  • 4SC AG
  • Fraunhoferstr. 22
  • 82152 Planegg-Martinsried

4SC presents clinical data on 4SC-201 at two specialised conferences in Geneva and Boston

(lifePR) (Planegg-Martinsried, ) The Martinsried-based drug discovery and development company 4SC AG (Frankfurt, Prime Standard: VSC) announced today that it will present the first clinical data of a phase I study on the drug candidate 4SC-201 for the treatment of cancer patients at two conferences at the end of October.

Organising the first conference entitled 'Molecular Targets and Cancer Therapeutics' are the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR). This conference will take place from 21 to 24 October 2008 at the Geneva Palexpo in Geneva, Switzerland.

The second conference, 'HDAC Inhibitors', is being organised by the Cambridge Healthtech Institute and will take place on 22 and 23 October 2008 in the World Trade Centre in Boston.

During these two conferences, 4SC AG will present data on the safety, tolerability, pharmacokinetics and efficacy of the drug candidate 4SC-201 in the treatment of cancer patients from the phase I study.

About 4SC-201:

4SC-201 is a substance from the class of the histone deacetylase (HDAC) inhibitors. It therefore concerns a drug candidate with which this clinical study had begun previously under the designation BYK408740.

This study, which is being conducted at the Royal Marsden Hospital in Sutton near London under the direction of Professor J. S. de Bono and which is nearing its conclusion, is primarily testing the safety and tolerability of 4SC-201.

Preclinical models have already shown 4SC-201 to have a very good safety profile and a highly efficacious anti-tumour activity. In comparison with other drug candidates also based on the inhibition of these HDAC enzymes, 4SC-201 shows in these models particularly good pharmacokinetic properties upon oral administration. Areas of application for the planned efficacy studies in clinical phase II trials will target various tumour diseases, for which there is great demand for treatment.


4SC AG (ISIN DE0005753818) has been listed in the Prime Standard of Frankfurt Stock Exchange since 15 December 2005. Founded in 1997 and now with a staff of 77 employees, the company develops novel drug candidates against inflammatory diseases and cancer. 4SC AG utilises its patent protected platform, to create a sustainable project pipeline of drug candidates, which are to be developed up to clinical efficacy in early clinical phases ('proof of concept') and subsequently partnered with the pharmaceutical industry in return for advance and milestone payments as well as royalties. There are currently eight projects in the development pipeline and a rich pool of further discovery projects. Clinical phase IIa for the first project for the treatment of rheumatoid arthritis has already successfully been completed. An additional project for the treatment of various cancers is currently completing a clinical phase I trial. Further projects are in advanced pre-clinical stages.

Further information is to be found at